Advertisement

Research Article Free access | 10.1172/JCI118039

Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine.

K A Foon, M Chakraborty, W J John, A Sherratt, H Köhler, and M Bhattacharya-Chatterjee

Lucille Parker Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536-0093, USA.

Find articles by Foon, K. in: JCI | PubMed | Google Scholar

Lucille Parker Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536-0093, USA.

Find articles by Chakraborty, M. in: JCI | PubMed | Google Scholar

Lucille Parker Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536-0093, USA.

Find articles by John, W. in: JCI | PubMed | Google Scholar

Lucille Parker Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536-0093, USA.

Find articles by Sherratt, A. in: JCI | PubMed | Google Scholar

Lucille Parker Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536-0093, USA.

Find articles by Köhler, H. in: JCI | PubMed | Google Scholar

Lucille Parker Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536-0093, USA.

Find articles by Bhattacharya-Chatterjee, M. in: JCI | PubMed | Google Scholar

Published July 1, 1995 - More info

Published in Volume 96, Issue 1 on July 1, 1995
J Clin Invest. 1995;96(1):334–342. https://doi.org/10.1172/JCI118039.
© 1995 The American Society for Clinical Investigation
Published July 1, 1995 - Version history
View PDF
Abstract

We have generated an IgG1 murine monoclonal anti-idiotype antibody (Ab2) designated 3H1, which mimics a specific epitope on the carcinoembryonic antigen (CEA). Patients with CEA positive tumors are immunologically "tolerant" to CEA. We used 3H1 as a surrogate for CEA for vaccine therapy of 12 patients with advanced colorectal cancer. Each of the patients received a minimum of four intracutaneous injections of aluminum hydroxide precipitated 3H1 at either 1, 2, or 4 mg dosage per injection. 9 of 12 patients demonstrated anti-anti-idiotypic (Ab3) response to 3H1. All nine patients generated specific anti-CEA antibody demonstrated by reactivity with radiolabeled purified CEA; some cases were confirmed by immunoprecipitation of purified CEA. We also demonstrated Ab3 stained both autologous and allogeneic colonic tumors. 7 of 12 patients demonstrated idiotype specific T cell proliferative responses and four also showed T cell proliferation to CEA. Toxicity was limited to local reaction with mild fever and chills. All 12 patients eventually progressed after finishing 4-13 dosages. This is the first report demonstrating that a vaccine therapy is capable of breaking "immune tolerance" to CEA in patients with CEA positive tumors. Future studies will focus on treating patients with minimal residual disease.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (July 1, 1995): No description
Advertisement
Advertisement